Conference item icon

Conference item

Experimental dissidence: economies of credibility in drug regulation

Abstract:

In 2004, a former FDA medical officer named David Ross watched news coverage of one of the highest-profile pharmaceutical controversies in recent years: Merck’s withdrawal of Vioxx, its bestselling painkiller, from the global marketplace. At the time, David Ross railed to his wife about the actions of David Graham, an associate director of drug safety at the FDA who drew international attention for testifying before the US Senate about the FDA’s handling of Vioxx. Graham said his supervisors...

Expand abstract

Actions


Authors


Publication date:
2010-01-15
UUID:
uuid:b642cfcc-5489-457c-bfb4-a55315eb29d1
Local pid:
oai:eureka.sbs.ox.ac.uk:382
Deposit date:
2011-05-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP